Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging StudyAsit Parikh, Brian G. Feagan, Timothy Leach et al.|Inflammatory Bowel Diseases|2011Cited by 211
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel DiseaseAsit Parikh, Brian G. Feagan, Irving H. Fox et al.|Inflammatory Bowel Diseases|2013Cited by 80
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy VolunteersMaria Rosario, Brian G. Feagan, Catherine Scholz et al.|Clinical Drug Investigation|2016Cited by 44
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research DatabaseMegan McAuliffe, Irving H. Fox, Stephan Lanes et al.|Current Medical Research and Opinion|2015Cited by 42
Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBDBrian G. Feagan, Irving H. Fox, Timothy Leach et al.|Inflammatory Bowel Diseases|2009Cited by 6